Fucoxanthin Enhances Cisplatin-Induced Cytotoxicity via NFκB-Mediated Pathway and Downregulates DNA Repair Gene Expression in Human Hepatoma HepG2 Cells
Cisplain, a platinum-containing anticancer drug, has been shown to enhance DNA repair and to inhibit cell apoptosis, leading to drug resistance. Thus, the combination of anticancer drugs with nutritional factors is a potential strategy for improving the efficacy of cisplatin chemotherapy. In this study, we investigated the anti-proliferative effects of a combination of fucoxanthin, the major non-provitamin A carotenoid found in Undaria Pinnatifida, and cisplatin in human hepatoma HepG2 cells. We found that fucoxanthin (1–10 μΜ) pretreatment for 24 h followed by cisplatin (10 μΜ) for 24 h significantly decreased cell proliferation, as compared with cisplatin treatment alone. Mechanistically, we showed that fucoxanthin attenuated cisplatin-induced NFκB expression and enhanced the NFκB-regulated Bax/Bcl-2 mRNA ratio. Cisplatin alone induced mRNA expression of excision repair cross complementation 1 (ERCC1) and thymidine phosphorylase (TP) through phosphorylation of ERK, p38 and PI3K/AKT pathways. However, fucoxanthin pretreatment significantly attenuated cisplatin-induced ERCC1 and TP mRNA expression, leading to improvement of chemotherapeutic efficacy of cisplatin. The results suggest that a combined treatment with fucoxanthin and cisplatin could lead to a potentially important new therapeutic strategy against human hepatoma cells.
References
[1]
Di Bisceglie, A.M. Epidemiology and clinical presentation of hepatocellular carcinoma. J. Vasc. Interv. Radiol. 2002, 13, S169–S171, doi:10.1016/S1051-0443(07)61783-7.
[2]
Montalto, G.; Cervello, M.; Giannitrapani, L.; Dantona, F.; Terranova, A.; Castagnetta, L.A. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann. N. Y. Acad. Sci. 2002, 963, 13–20.
[3]
Chau, G.Y.; Lui, W.Y.; Tsay, S.H.; Chao, Y.; King, K.L.; Wu, C.W. Postresectional adjuvant intraportal chemotherapy in patients with hepatocellular carcinoma: A case-control study. Ann. Surg. Oncol. 2006, 13, 1329–1337, doi:10.1245/s10434-006-9004-1.
[4]
Tong, S.W.; Yang, Y.X.; Hu, H.D.; An, X.; Ye, F.; Hu, P.; Ren, H.; Li, S.L.; Zhang, D.Z. Proteomic investigation of 5-fluorouracil resistance in a human hepatocellular carcinoma cell line. J. Cell. Biochem. 2012, 113, 1671–1680.
[5]
Dietel, M. Molecular mechanisms and possibilities of overcoming drug resistance in gastrointestinal tumors. Recent Results Cancer Res. 1996, 142, 89–101, doi:10.1007/978-3-642-80035-1_7.
[6]
Go, R.S.; Adjei, A.A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J. Clin. Oncol. 1999, 17, 409–422.
Zorbas, H.; Keppler, B.K. Cisplatin damage: Are DNA repair proteins saviors or traitors to the cell? ChemBioChem 2005, 6, 1157–1166, doi:10.1002/cbic.200400427.
[9]
Van de Vaart, P.J.; van der Vange, N.; Zoetmulder, F.A.; van Goethem, A.R.; van Tellingen, O.; ten Bokkel Huinink, W.W.; Beijnen, J.H.; Bartelink, H.; Begg, A.C. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur. J. Cancer 1998, 34, 148–154.
[10]
Kartalou, M.; Essigmann, J.M. Mechanisms of resistance to cisplatin. Mutat. Res. 2001, 478, 23–43, doi:10.1016/S0027-5107(01)00141-5.
[11]
Shahzad, M.M.; Lopez-Berestein, G.; Sood, A.K. Novel strategies for reversing platinum resistance. Drug Resist. Updat. 2009, 12, 148–152, doi:10.1016/j.drup.2009.09.001.
[12]
Helleday, T.; Petermann, E.; Lundin, C.; Hodgson, B.; Sharma, R.A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 2008, 8, 193–204, doi:10.1038/nrc2342.
[13]
Rabik, C.A.; Dolan, M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 2007, 33, 9–23, doi:10.1016/j.ctrv.2006.09.006.
[14]
Shirota, Y.; Stoehlmacher, J.; Brabender, J.; Xiong, Y.P.; Uetake, H.; Danenberg, K.D.; Groshen, S.; Tsao-Wei, D.D.; Danenberg, P.V.; Lenz, H.J. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 2001, 19, 4298–4304.
[15]
Lord, R.V.; Brabender, J.; Gandara, D.; Alberola, V.; Camps, C.; Domine, M.; Cardenal, F.; Sanchez, J.M.; Gumerlock, P.H.; Taron, M.; et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 2002, 8, 2286–2291.
[16]
Zhou, W.; Gurubhagavatula, S.; Liu, G.; Park, S.; Neuberg, D.S.; Wain, J.C.; Lynch, T.J.; Su, L.; Christiani, D.C. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res. 2004, 10, 4939–4943.
[17]
Selvakumaran, M.; Pisarcik, D.A.; Bao, R.; Yeung, A.T.; Hamilton, T.C. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 2003, 63, 1311–1316.
[18]
Gossage, L.; Madhusudan, S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat. Rev. 2007, 33, 565–577, doi:10.1016/j.ctrv.2007.07.001.
Nakayama, Y.; Inoue, Y.; Nagashima, N.; Katsuki, T.; Matsumoto, K.; Kadowaki, K.; Shibao, K.; Tsurudome, Y.; Hirata, K.; Sako, T.; et al. Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancer. Anticancer Res. 2005, 25, 3755–3761.
[21]
Mori, S.; Takao, S.; Ikeda, R.; Noma, H.; Mataki, Y.; Wang, X.; Akiyama, S.; Aikou, T. Thymidine phosphorylase suppresses Fas-induced apoptotic signal transduction independent of its enzymatic activity. Biochem. Biophys. Res. Commun. 2002, 295, 300–305, doi:10.1016/S0006-291X(02)00662-9.
[22]
Ikeda, R.; Furukawa, T.; Mitsuo, R.; Noguchi, T.; Kitazono, M.; Okumura, H.; Sumizawa, T.; Haraguchi, M.; Che, X.F.; Uchimiya, H.; et al. Thymidine phosphorylase inhibits apoptosis induced by cisplatin. Biochem. Biophys. Res. Commun. 2003, 301, 358–363, doi:10.1016/S0006-291X(02)03034-6.
[23]
Jeung, H.C.; Che, X.F.; Haraguchi, M.; Furukawa, T.; Zheng, C.L.; Sumizawa, T.; Rha, S.Y.; Roh, J.K.; Akiyama, S. Thymidine phosphorylase suppresses apoptosis induced by microtubule-interfering agents. Biochem. Pharmacol. 2005, 70, 13–21.
[24]
Baldwin, A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J. Clin. Investig. 2001, 107, 241–246, doi:10.1172/JCI11991.
[25]
Tabruyn, S.P.; Griffioen, A.W. A new role for NF-κB in angiogenesis inhibition. Cell. Death Differ. 2007, 14, 1393–1397, doi:10.1038/sj.cdd.4402156.
[26]
Andela, V.B.; Gordon, A.H.; Zotalis, G.; Rosier, R.N.; Goater, J.J.; Lewis, G.D.; Schwarz, E.M.; Puzas, J.E.; O’Keefe, R.J. NFκB: A pivotal transcription factor in prostate cancer metastasis to bone. Clin. Orthop. Relat. Res. 2003, 415 (Suppl.), S75–S85.
[27]
Tomita, M.; Kawakami, H.; Uchihara, J.N.; Okudaira, T.; Masuda, M.; Takasu, N.; Matsuda, T.; Ohta, T.; Tanaka, Y.; Ohshiro, K.; et al. Curcumin (diferuloylmethane) inhibits constitutive active NF-κB, leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells. Int. J. Cancer 2006, 118, 765–772, doi:10.1002/ijc.21389.
[28]
Sharma, H.W.; Narayanan, R. The NF-κB transcription factor in oncogenesis. Anticancer Res. 1996, 16, 589–596.
[29]
Nakanishi, C.; Toi, M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 2005, 5, 297–309, doi:10.1038/nrc1588.
[30]
Shou, Y.; Li, N.; Li, L.; Borowitz, J.L.; Isom, G.E. NF-κB-mediated up-regulation of Bcl-XS and Bax contributes to cytochrome c release in cyanide-induced apoptosis. J. Neurochem. 2002, 81, 842–852, doi:10.1046/j.1471-4159.2002.00880.x.
[31]
Sarkar, F.H.; Li, Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res. 2006, 66, 3347–3350, doi:10.1158/0008-5472.CAN-05-4526.
[32]
Yeh, P.Y.; Chuang, S.E.; Yeh, K.H.; Song, Y.C.; Cheng, A.L. Involvement of nuclear transcription factor-κB in low-dose doxorubicin-induced drug resistance of cervical carcinoma cells. Biochem. Pharmacol. 2003, 66, 25–33.
[33]
Dembitsky, V.M.; Maoka, T. Allenic and cumulenic lipids. Prog. Lipid Res. 2007, 46, 328–375, doi:10.1016/j.plipres.2007.07.001.
[34]
Sachindra, N.M.; Sato, E.; Maeda, H.; Hosokawa, M.; Niwano, Y.; Kohno, M.; Miyashita, K. Radical scavenging and singlet oxygen quenching activity of marine carotenoid fucoxanthin and its metabolites. J. Agric. Food Chem. 2007, 55, 8516–8522, doi:10.1021/jf071848a.
[35]
Heo, S.J.; Jeon, Y.J. Protective effect of fucoxanthin isolated from Sargassum siliquastrum on UV-B induced cell damage. J. Photochem. Photobiol. B 2009, 95, 101–107, doi:10.1016/j.jphotobiol.2008.11.011.
[36]
Liu, C.L.; Liang, A.L.; Hu, M.L. Protective effects of fucoxanthin against ferric nitrilotriacetate-induced oxidative stress in murine hepatic BNL CL.2 cells. Toxicol. In Vitro 2011, 25, 1314–1319, doi:10.1016/j.tiv.2011.04.023.
[37]
Liu, C.L.; Chiu, Y.T.; Hu, M.L. Fucoxanthin enhances HO-1 and NQO1 expression in murine hepatic BNL CL.2 cells through activation of the Nrf2/ARE system partially by its pro-oxidant activity. J. Agric. Food Chem. 2011, 59, 11344–11351.
[38]
Maeda, H.; Hosokawa, M.; Sashima, T.; Takahashi, N.; Kawada, T.; Miyashita, K. Fucoxanthin and its metabolite, fucoxanthinol, suppress adipocyte differentiation in 3T3-L1 cells. Int. J. Mol. Med. 2006, 18, 147–152.
[39]
Jeon, S.M.; Kim, H.J.; Woo, M.N.; Lee, M.K.; Shin, Y.C.; Park, Y.B.; Choi, M.S. Fucoxanthin-rich seaweed extract suppresses body weight gain and improves lipid metabolism in high-fat-fed C57BL/6J mice. Biotechnol. J. 2010, 5, 961–969, doi:10.1002/biot.201000215.
[40]
Maeda, H.; Hosokawa, M.; Sashima, T.; Miyashita, K. Dietary combination of fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and decreases blood glucose in obese/diabetic KK-Ay mice. J. Agric. Food Chem. 2007, 55, 7701–7706, doi:10.1021/jf071569n.
[41]
Nishino, H.; Tokuda, H.; Murakoshi, M.; Satomi, Y.; Masuda, M.; Onozuka, M.; Yamaguchi, S.; Takayasu, J.; Tsuruta, J.; Okuda, M.; et al. Cancer prevention by natural carotenoids. Biofactors 2000, 13, 89–94, doi:10.1002/biof.5520130115.
[42]
Kim, K.N.; Heo, S.J.; Yoon, W.J.; Kang, S.M.; Ahn, G.; Yi, T.H.; Jeon, Y.J. Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF-κB and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophages. Eur. J. Pharmacol. 2010, 649, 369–375, doi:10.1016/j.ejphar.2010.09.032.
[43]
Zaragoza, M.C.; Lopez, D.; Sa？iz, M.P.; Poquet, M.; Perez, J.; Puig-Parellada, P.; Marmol, F.; Simonetti, P.; Gardana, C.; Lerat, Y.; et al. Toxicity and antioxidant activity in vitro and in vivo of two Fucus vesiculosus extracts. J. Agric. Food Chem. 2008, 56, 7773–7780.
[44]
Yu, R.X.; Hu, X.M.; Xu, S.Q.; Jiang, Z.J.; Yang, W. Effects of fucoxanthin on proliferation and apoptosis in human gastric adenocarcinoma MGC-803 cells via JAK/STAT signal pathway. Eur. J. Pharmacol. 2011, 657, 10–19, doi:10.1016/j.ejphar.2010.12.006.
[45]
Satomi, Y.; Nishino, H. Implication of mitogen-activated protein kinase in the induction of G1 cell cycle arrest and gadd45 expression by the carotenoid fucoxanthin in human cancer cells. Biochim. Biophys. Acta 2009, 1790, 260–266, doi:10.1016/j.bbagen.2009.01.003.
[46]
Das, S.K.; Hashimoto, T.; Kanazawa, K. Growth inhibition of human hepatic carcinoma HepG2 cells by fucoxanthin is associated with down-regulation of cyclin D. Biochim. Biophys. Acta 2008, 1780, 743–749, doi:10.1016/j.bbagen.2008.01.003.
[47]
Yoshiko, S.; Hoyoku, N. Fucoxanthin, a natural carotenoid, induces G1 arrest and GADD45 gene expression in human cancer cells. In Vivo 2007, 21, 305–309.
[48]
Liu, C.L.; Lim, Y.P.; Hu, M.L. Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells. Mar. Drugs 2012, 10, 242–257, doi:10.3390/md10010242.
[49]
Viatour, P.; Bentires-Alj, M.; Chariot, A.; Deregowski, V.; de Leval, L.; Merville, M.P.; Bours, V. NF-κB2/p100 induces Bcl-2 expression. Leukemia 2003, 17, 1349–1356, doi:10.1038/sj.leu.2402982.
[50]
Minn, A.J.; Rudin, C.M.; Boise, L.H.; Thompson, C.B. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 1995, 86, 1903–1910.
[51]
Altaha, R.; Liang, X.; Yu, J.J.; Reed, E. Excision repair cross complementing-group 1: Gene expression and platinum resistance. Int. J. Mol. Med. 2004, 14, 959–970.
[52]
Ko, J.C.; Su, Y.J.; Lin, S.T.; Jhan, J.Y.; Ciou, S.C.; Cheng, C.M.; Chiu, Y.F.; Kuo, Y.H.; Tsai, M.S.; Lin, Y.W. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2. Lung Cancer 2010, 69, 155–164, doi:10.1016/j.lungcan.2009.10.013.
[53]
Tsai, M.S.; Weng, S.H.; Kuo, Y.H.; Chiu, Y.F.; Lin, Y.W. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1). Mol. Pharmacol. 2011, 80, 136–146, doi:10.1124/mol.111.071316.
[54]
Zhang, W.; Liu, H.T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002, 12, 9–18, doi:10.1038/sj.cr.7290105.
[55]
Basu, A.; Tu, H. Activation of ERK during DNA damage-induced apoptosis involves protein kinase Cδ. Biochem. Biophys. Res. Commun. 2005, 334, 1068–1073, doi:10.1016/j.bbrc.2005.06.199.
[56]
Datta, S.R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91, 231–241, doi:10.1016/S0092-8674(00)80405-5.
[57]
Mabuchi, S.; Ohmichi, M.; Nishio, Y.; Hayasaka, T.; Kimura, A.; Ohta, T.; Saito, M.; Kawagoe, J.; Takahashi, K.; Yada-Hashimoto, N.; et al. Inhibition of NFκB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J. Biol. Chem. 2004, 279, 23477–23485.
[58]
Ohta, T.; Ohmichi, M.; Hayasaka, T.; Mabuchi, S.; Saitoh, M.; Kawagoe, J.; Takahashi, K.; Igarashi, H.; Du, B.; Doshida, M.; et al. Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. Endocrinology 2006, 147, 1761–1769.
[59]
Andrieux, L.O.; Fautrel, A.; Bessard, A.; Guillouzo, A.; Baffet, G.; Langouet, S. GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells. Cancer Res. 2007, 67, 2114–2123.
[60]
Bessard, A.; Coutant, A.; Rescan, C.; Ezan, F.; Fremin, C.; Courselaud, B.; Ilyin, G.; Baffet, G. An MLCK-dependent window in late G1 controls S phase entry of proliferating rodent hepatocytes via ERK-p70S6K pathway. Hepatology 2006, 44, 152–163, doi:10.1002/hep.21222.
[61]
Chen, C.C.; Chen, L.C.; Liang, Y.; Tsang, N.M.; Chang, Y.S. Epstein-Barr virus latent membrane protein 1 induces the chemotherapeutic target, thymidine phosphorylase, via NF-κB and p38 MAPK pathways. Cell. Signal. 2010, 22, 1132–1142, doi:10.1016/j.cellsig.2010.03.008.
[62]
Liu, C.L.; Huang, Y.S.; Hosokawa, M.; Miyashita, K.; Hu, M.L. Inhibition of proliferation of a hepatoma cell line by fucoxanthin in relation to cell cycle arrest and enhanced gap junctional intercellular communication. Chem. Biol. Interact. 2009, 182, 165–172, doi:10.1016/j.cbi.2009.08.017.
[63]
Lin, C.Y.; Huang, C.S.; Hu, M.L. The use of fetal bovine serum as delivery vehicle to improve the uptake and stability of lycopene in cell culture studies. Br. J. Nutr. 2007, 98, 226–232, doi:10.1017/S0007114507691752.
[64]
Lim, Y.P.; Kuo, S.C.; Lai, M.L.; Huang, J.D. Inhibition of CYP3A4 expression by ketoconazole is mediated by the disruption of pregnane X receptor, steroid receptor coactivator-1, and hepatocyte nuclear factor 4alpha interaction. Pharmacogenetics Genomics 2009, 19, 11–24, doi:10.1097/FPC.0b013e32831665ea.
[65]
Chen, Y.C.; Kuo, T.C.; Lin-Shiau, S.Y.; Lin, J.K. Induction of HSP70 gene expression by modulation of Ca(+2) ion and cellular p53 protein by curcumin in colorectal carcinoma cells. Mol. Carcinog. 1996, 17, 224–234, doi:10.1002/(SICI)1098-2744(199612)17:4<224::AID-MC6>3.0.CO;2-D.
[66]
Shukla, S.; Maclennan, G.T.; Marengo, S.R.; Resnick, M.I.; Gupta, S. Constitutive activation of P I3 K-Akt and NF-κB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 2005, 64, 224–239, doi:10.1002/pros.20217.
